Challenges in Managing the Ocular Complications of Stevens-Johnson Syndrome in Patients with Co-Existent Auto-Immune Disease

Chronic ocular complications of SJS require tailored immunosuppressive strategies, particularly in patients with preexisting autoimmune diseases. Early identification of disease patterns and co-management with rheumatologists are crucial. Rituximab and MMF may provide long-term disease control, but discontinuation of IMT should be approached cautiously to prevent recurrence. Further research is needed to optimize treatment protocols and determine the ideal duration of systemic therapy in chronic ocular SJS.